Chinook Therapeutics Report issue

For profit Phase 2 Phase 3
Founded: Vancouver Canada (2019)
Status: Acquired by Aduro BioTech (2020)

Organization Overview

First Clinical Trial
2020
NCT04684745
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Chinook Therapeutics | Chinook Therapeutics, Inc. | Chinook Therapeutics U.S., Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

atrasentan hydrochloride (2 trials)

Drugs in Phase 2 Trials (1)

bion-1301 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glomerulonephritis, IGA (Phase 3)

Kidney Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2